0001193125-26-166843
SEC filingRevenue growth of 57% YoY driven by new patient starts and PBP channel mix shift, with gross margin expanding 800 bps to 59.5%.
For the three months ended March 31, 2026, Beta Bionics reported net sales of $27.6 million, a 57% increase from $17.6 million in the prior-year period. The growth was driven by a higher volume of single-use products (cartridges and infusion sets) correlated with an expanding installed base of iLet users, as well as an increase in new patient starts. Single-use products accounted for 62% of net sales, up from 43% in Q1 2025.
Gross profit rose 83% to $16.4 million, with gross margin expanding to 59.5% from 50.9% a year ago. The improvement was attributed to increased production scale, better manufacturing cost absorption, and material cost savings, which more than offset the impact of a continued shift toward the pharmacy benefit plan (PBP) channel, where initial device sales carry negative gross margins.
Operating expenses increased 47% to $40.7 million, reflecting investments in commercialization and innovation. Research and development expenses rose 36% to $10.4 million, driven by higher headcount and costs for patch pump and bihormonal system development. Sales and marketing expenses grew 55% to $20.7 million, primarily due to expansion of the sales force and customer care team. General and administrative expenses increased 45% to $9.6 million, driven by payroll, professional fees, and quality system remediation costs.
Net loss improved to $21.9 million from $28.7 million in Q1 2025, aided by the absence of a $12.5 million non-cash loss from the change in fair value of warrant liabilities that occurred in the prior year.
Beta Bionics operates through two primary reimbursement channels: durable medical equipment (DME) and pharmacy benefit plan (PBP). In Q1 2026, the DME channel represented 61% of net sales (down from 78% in Q1 2025), while the PBP channel grew to 39% (up from 22%). The shift reflects expanded pharmacy benefit coverage and the company's strategic priority to direct demand toward the PBP channel, which yields more favorable lifetime economics despite initial negative gross margins. PBP-reimbursed new patient starts reached the high-30% range in Q1 2026, up from low-20% in Q1 2025.
Management expects operating expenses to increase significantly as the company continues to invest in commercialization, R&D for new products (patch pump, bihormonal system, T2D indication), and public company infrastructure. The company believes existing cash, cash equivalents, and investments of $239.5 million, combined with product revenue, will fund operations through the first half of 2028. Key strategic priorities include expanding PBP channel penetration, growing the sales force, and advancing clinical development of next-generation products. The company also faces regulatory headwinds, including a January 2026 FDA Warning Letter related to quality system deficiencies, which has prompted remediation expenses.
As of March 31, 2026, the Company held $209.2 million in marketable securities (U.S. Treasury bills and notes) classified as short-term ($169.3M) and long-term ($39.9M). Cash equivalents were $24.3 million. Inventories stood at $23.7 million, consisting of raw materials ($8.8M), work in process ($2.5M), and finished goods ($12.4M). Accounts receivable net was $15.8 million, with an allowance for credit losses of $0.2 million. Total assets were $304.4 million, while total liabilities were $33.2 million. Stockholders' equity was $271.2 million.
The Company has a collaboration and license agreement with Xeris requiring future development and manufacturing costs totaling $5.1 million, of which $4.0 million has been paid as of March 31, 2026, leaving a remaining commitment of $1.1 million. Additionally, operating lease obligations total $8.3 million in future payments, with $1.5 million due in the remainder of 2026. Warranty reserves of $3.2 million are recorded.
No share buyback programs or dividends were disclosed. The Company has no outstanding debt. Capital expenditures are not separately disclosed in the notes; however, property and equipment net increased to $10.2 million.
The Company operates as a single segment. The CODM uses net loss as the primary measure of segment profit or loss. All revenues are domestic; no international revenues or material assets outside the U.S. were reported.